RxDoctor Payments Data

Thomas Larsen, MD

Family Medicine · South Bend, INNPI 1285998146

Payments from drug & device makers

$708in general payments, 2019–2025

Across 25 payments — averaging $28.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$174
  • Abbott$168
  • Novo Nordisk$76
  • Indivior Inc.$39
  • Pfizer$36
  • AstraZeneca$30
  • plus $185 from 8 others

What the payments were for

  • Food & beverage$69798%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$708 in reported general payments places this provider in the 55th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$118,606
Medicare patients
215
Services billed
3,437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$92,394
OzempicSemaglutide58$82,498
JanuviaSitagliptin Phosphate29$47,604
MounjaroTirzepatide34$42,904
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$37,768
TrulicityDulaglutide14$26,427
JardianceEmpagliflozin11$21,769
Breo ElliptaFluticasone/Vilanterol38$16,647
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$15,422
Lantus SolostarInsulin Glargine,hum.Rec.Anlog69$12,521
Tresiba Flextouch U-100Insulin Degludec19$10,925
BrilintaTicagrelor23$6,770
SymbicortBudesonide/Formoterol Fumarate23$6,334
Novolog FlexpenInsulin Aspart21$5,192
LipitorAtorvastatin Calcium11$4,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lipitor$36$97,22882 claims
Novo NordiskOzempic$76$82,49858 claims
Lilly USA, LLCMounjaro, Trulicity$19$69,33148 claims
AstraZenecaBreztri Aerosphere, Brilinta, Symbicort$30$28,52769 claims
Boehringer IngelheimJardiance$20$21,76911 claims
AbbVieSynthroid$26$2,05529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →